Clinical Trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Study acronym: MOVE-Lp(a)
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Protocol Amendment History 4 changes
notable Trial sites expanded: 769 -> 772 locations 2026-07-21
notable Trial sites expanded: 762 -> 769 locations 2026-07-08
notable Trial sites expanded: 752 -> 762 locations 2026-06-24
notable Trial sites expanded: 751 -> 754 locations 2026-05-13
Trial Details
NCT Number NCT07157774
Lead Sponsor Eli Lilly and Company
Conditions Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Enrollment 10,450 participants
Start Date 2025-09-02
Primary Completion 2031-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20